Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP492276.RAv8vxlfa3Ax3-kS5IZlERGwfIB6Uk1pP1XIJul7MJd-M130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP492276.RAv8vxlfa3Ax3-kS5IZlERGwfIB6Uk1pP1XIJul7MJd-M130_assertion type Assertion NP492276.RAv8vxlfa3Ax3-kS5IZlERGwfIB6Uk1pP1XIJul7MJd-M130_head.
- NP492276.RAv8vxlfa3Ax3-kS5IZlERGwfIB6Uk1pP1XIJul7MJd-M130_assertion description "[Specifically, drugs targeting VEGF (bevacizumab, sunitinib, sorafenib, axitinib, pazopanib) and PI3K-mTOR (temsirolimus and everolimus) have become the cornerstone of renal cancer treatment.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP492276.RAv8vxlfa3Ax3-kS5IZlERGwfIB6Uk1pP1XIJul7MJd-M130_provenance.
- NP492276.RAv8vxlfa3Ax3-kS5IZlERGwfIB6Uk1pP1XIJul7MJd-M130_assertion evidence source_evidence_literature NP492276.RAv8vxlfa3Ax3-kS5IZlERGwfIB6Uk1pP1XIJul7MJd-M130_provenance.
- NP492276.RAv8vxlfa3Ax3-kS5IZlERGwfIB6Uk1pP1XIJul7MJd-M130_assertion SIO_000772 20080466 NP492276.RAv8vxlfa3Ax3-kS5IZlERGwfIB6Uk1pP1XIJul7MJd-M130_provenance.
- NP492276.RAv8vxlfa3Ax3-kS5IZlERGwfIB6Uk1pP1XIJul7MJd-M130_assertion wasDerivedFrom befree-20140225 NP492276.RAv8vxlfa3Ax3-kS5IZlERGwfIB6Uk1pP1XIJul7MJd-M130_provenance.
- NP492276.RAv8vxlfa3Ax3-kS5IZlERGwfIB6Uk1pP1XIJul7MJd-M130_assertion wasGeneratedBy ECO_0000203 NP492276.RAv8vxlfa3Ax3-kS5IZlERGwfIB6Uk1pP1XIJul7MJd-M130_provenance.